Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dysadherin specific drug conjugates for the treatment of thyroid cancers with aggressive phenotypes.

Oncotarget - 11 Apr 2017

Jang Samuel, Yu Xiao-Min, Montemayor-Garcia Celina, Ahmed Kamal, Weinlander Eric, Lloyd Ricardo V, Dammalapati Ajitha, Marshall David, Prudent James R, Chen Herbert

Abstract excerpt

BACKGROUND: EDC1 is a novel type of antibody-drug conjugate which binds and inhibits the Na,K-ATPase on the surface of cancer cells expressing dysadherin. The purpose of this study was to determine the expression of dysadherin in different types of thyroid carcinoma, and evaluate the therapeutic potential of EDC1 for thyroid carcinomas. METHODS: Thyroid tissues from 158 patients were examined for dysadherin...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ion Channels

Share to Membrane Glycoproteins

Share to Microfilament Proteins

Share to Neoplasm Proteins

Share to Thyroid Neoplasms

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 28160550
DOI: 10.18632/oncotarget.14904
PMCID: PMC5421862

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Dysadherin specific drug conjugates for the treatment of thyroid cancers with aggressive phenotypes.PMID 28160550Read ↗

Let-7a Down-Regulation Plays a Role in Thyroid Neoplasias of Follicular Histotype Affecting Cell Adhesion and Migration through Its Ability to Target the<i>FXYD5</i>(Dysadherin) GeneSemantic proximity Read ↗

EpCAM silencing suppresses aggressive phenotypes and induces partial redifferentiation in anaplastic thyroid cancer cells.Semantic proximity Read ↗

Human anaplastic thyroid carcinoma cells are sensitive to NK cell-mediated lysis via ULBP2/5/6 and chemoattract NK cells.Semantic proximity Read ↗

Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis.Semantic proximity Read ↗

Effect of Combined Epigenetic Treatments and Ectopic NIS Expression on Undifferentiated Thyroid Cancer CellsSemantic proximity Read ↗

Overexpression of the NOTCH1 intracellular domain inhibits cell proliferation and alters the neuroendocrine phenotype of medullary thyroid cancer cells.Semantic proximity Read ↗

Motesanib diphosphate in progressive differentiated thyroid cancer.Semantic proximity Read ↗

Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer <i>in vitro</i> and <i>in vivo</i>Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.